Furthermore, EGFR is known to be upregulated in up to 69-95% of advanced pancreatic cancers [10, 11] and the EGFR tyrosine kinase inhibitor erlotinib combined with gemcitabine demonstrated survival benefit over gemcitabine alone [12]. Here, EGFR is linked to familial pancreatic carcinoma.